The Technical Analyst
Chiasma, Inc. [CHMA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Chiasma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.00% $3.76
America/New_York / 31 des 1970 @ 19:00
| RATING 2021-09-15 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/19 | 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.39 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.41x |
| Company: PE -2.39 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.60 - 3.92 ( +/- 4.23%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-05 | Stonepine Capital, L.p. | Sell | 6 770 000 | Common Stock |
| 2021-08-05 | Ludlam William | Sell | 11 799 | Common Stock |
| 2021-08-05 | Ludlam William | Sell | 45 916 | Stock Option (Right to Buy) |
| 2021-08-05 | Ludlam William | Sell | 14 531 | Stock Option (Right to Buy) |
| 2021-08-05 | Ludlam William | Sell | 74 997 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 99 transactions |
| Buy: 1 667 356 | Sell: 11 115 504 |
Forecast:
01:40 - $4.65
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.76 (-6.00% ) |
| Volume | 8.20 mill |
| Avg. Vol. | 0.996 mill |
| % of Avg. Vol | 822.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CHMA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CHMA
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2021-07-10 13:59:00 - Press Release
Investigation Alert: Halper Sadeh Llp Investigates Onem, Syke, Nete, Chma, Soly, Arpo; Shareholders Are Encouraged To Contact The Firm
New york , july 10, 2021 /prnewswire/ -- halper sadeh llp, a global investor rights law firm, announces it is investigating the following companies: 1life healthcare, inc. (nasdaq: onem) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with iora health. under the terms of the merger, 1life healthcare will acquire iora health in an all-stock transaction.
2021-06-28 16:12:00 - Press Release
Chiasma Announces Submission Of Marketing Authorization Application For Mycapssa® To The European Medicines Agency
Submission supported by previously announced data from phase 3 mpowered™ study submission supported by previously announced data from phase 3 mpowered™ study
2021-05-27 16:05:00 - Press Release
Chiasma Presents Positive Patient-reported Outcomes Data From Its Mpowered™ Phase 3 Trial Comparing Mycapssa® To Long-acting Injectables For The Maintenance Treatment Of Adults With Acromegaly
--data presented at aace 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable ssas to mycapssa®-- --data presented at aace 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable ssas to mycapssa®--
2021-05-20 08:00:00 - Press Release
Chiasma To Present Encore And New Data From Mpowered™ Phase 3 Trial At Upcoming E-ece And Aace Virtual Conferences
-- new clinical data accepted for oral and e-poster presentation at aace -- -- e-ece clinical data previously presented at endocrine society's 2021 annual meeting --
2021-05-13 18:41:00 - Press Release
Shareholder Investigation: Halper Sadeh Llp Investigates Ufs, Foe, Chma, Acst; Shareholders Are Encouraged To Contact The Firm
New york, may 13, 2021 /prnewswire/ -- halper sadeh llp, a global investor rights law firm, announces it is investigating the following companies: domtar corporation (nyse: ufs) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to paper excellence for $55.50 per share in cash. if you are a domtar shareholder, click here to learn more about your rights and options.
Latest News
2021-08-05 11:10:48 - Proactive Investors
Amryt Pharma completes Chiasma acquisition
Amryt Pharma PLC has completed its acquisition of US group Chiasma Inc with Raj Kannan and Roni Mamluk joining the board as non-executive directors. Joe Wiley, Amryt's chief executive, said: “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.
2021-07-10 13:59:00 - PRNewsWire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
NEW YORK , July 10, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: 1Life Healthcare, Inc. (NASDAQ: ONEM) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction.
2021-06-29 07:03:04 - Benzinga
Chiasma Files Mycapssa European Application For Acromegaly
Chiasma Inc (NASDAQ: CHMA) submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa (oral octreotide capsules) as maintenance therapy for adults with acromegaly. The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs (iSSAs).
2021-06-28 16:12:00 - GlobeNewsWire
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study
2021-05-28 08:02:41 - Benzinga
Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients
Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.
2021-05-27 16:05:00 - GlobeNewsWire
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--
2021-05-20 08:00:00 - GlobeNewsWire
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society's 2021 annual meeting --
2021-05-13 09:10:07 - Zacks Investment Research
Chiasma (CHMA) is Overbought: Is A Drop Coming?
Chiasma (CHMA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
2021-05-08 20:01:09 - Seeking Alpha
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
2021-05-07 21:00:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA
NEW YORK, May 7, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Chiasma, Inc. ("CHMA" or the "Company") ( CHMA ) relating to its proposed acquisition by Amryt Pharma plc. Under the terms of the agreement, CHMA shareholders will receive 0.396 Amryt American Depositary Share, each representative of five Amryt ordinary shares, per share they own.